HDAC9 and cancer: Recently, pomiferin has been demonstrated to inhibit HDAC enzyme activity at low micromolar concentrations (IC50 approx. 1 μM) and to inhibit growth of different human cancer cell lines, e.g. kidney, lung, prostate, breast or colon cancer, without affecting the growth of primary human hepatocytes (47).